Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.78

0.0%

Dec 31 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1969)	10/15/2007 10:39:04 AM
From: Jibacoa	Read Replies (1) of 3722

IMMU has formed a base at the $2.25 level & is up 15% today. bigcharts.marketwatch.com No special news that I am aware. Today's volume is already close to its ADV. With some good news it seems that the stock could get back to the $5 level.<g> bigcharts.marketwatch.com In July it was reported that Epratuzumab preferentially modulates the exaggerated activation and proliferation of B cells from SLE patients in contrast to normal subjects, suggesting that it might offer a new therapeutic option for patients with SLE, since enhanced B-cell activation is a hallmark of the disease. In Sep 2006 UCB put a hold on epratuzumab production because of concerns about sterility in its manufacturing. Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next